RESUMO
Our previous findings suggest that alpha(2)-adrenoceptor stimulants induce gastroprotective action, the effect is likely to be mediated by alpha(2B)-adrenoceptor subtype. Clonidine (0.094 micromol/kg p.o.) and rilmenidine (0.014 micromol/kg p.o.) in gastroprotective dose range, as well as ST-91 (2.2 micromol/kg p.o.), a clonidine analogue showing higher affinity to alpha(2B)-adrenoceptor subtype than to alpha(2A)-one, inhibited the carrageenan-induced hyperalgesia in Randall-Selitto test, the antinociceptive action was reversed by yohimbine (5 micromol/kg s.c.) and the alpha(2B)-adrenoceptor antagonist prazosin (0.24 micromol/kg i.p.). Similarly, clonidine and rilmenidine in the same dose range reduced the oedema formation induced by carrageenan, yohimbine and the alpha(2A)-adrenoceptor antagonist BRL-44408 (3 micromol/kg i.p.) inhibited the anti-inflammatory effect; however, prazosin failed to affect it. These results suggest that alpha(2B/C)-like adrenoceptor subtype may be involved in the antihyperalgesic action, but not in the antiphlogistic effect of alpha(2)-adrenoceptor stimulants. The later effect may be mediated by alpha(2A)-like adrenoceptor subtype.
Assuntos
Agonistas de Receptores Adrenérgicos alfa 2 , Analgésicos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Antiulcerosos/uso terapêutico , Edema/tratamento farmacológico , Hiperalgesia/tratamento farmacológico , Úlcera Gástrica/tratamento farmacológico , Antagonistas de Receptores Adrenérgicos alfa 2 , Agonistas alfa-Adrenérgicos/uso terapêutico , Animais , Clonidina/análogos & derivados , Clonidina/uso terapêutico , Modelos Animais de Doenças , Edema/induzido quimicamente , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/fisiologia , Hiperalgesia/induzido quimicamente , Masculino , Oxazóis/uso terapêutico , Ratos , Ratos Wistar , Receptores Adrenérgicos alfa 2/fisiologia , Rilmenidina , Úlcera Gástrica/induzido quimicamenteRESUMO
SSAO/VAP-1 is not only involved in the metabolism of biogenic and xenobiotic primary amines and in the production of metabolites with cytotoxic effects or certain physiological actions, but also plays a role, for example, as an adhesion molecule, in leukocyte trafficking, in regulating glucose uptake and in adipocyte homeostasis. Interest in the enzyme has been stimulated by the findings that the activities of the SSAOs are altered (mostly increased) in various human disorders, including diabetes, congestive heart failure, liver cirrhosis, Alzheimer's disease and several inflammatory diseases, although the underlying causes are often unknown. On the basis of their insulin-mimicking effect, SSAO substrates are possibly capable of ameliorating metabolic changes in diabetes, while SSAO inhibitors (somewhat of a contradiction) are of potential benefit in preventing diabetes complications, atherosclerosis and oxidative stress contributing to several disorders or modulating inflammation, and hence may be of substantial therapeutic value. Great efforts have been made to develop novel compounds which may lead to future drugs useful in therapy, based on their effects on SSAO/VAP-1, and some of the results relating to novel substrates and inhibitors are surveyed in the present review.
Assuntos
Amina Oxidase (contendo Cobre)/antagonistas & inibidores , Amina Oxidase (contendo Cobre)/química , Monoaminoxidase/química , Semicarbazidas/química , Doença de Alzheimer/tratamento farmacológico , Amina Oxidase (contendo Cobre)/metabolismo , Aminas/química , Animais , Sangue/metabolismo , Bovinos , Moléculas de Adesão Celular/metabolismo , Diabetes Mellitus/tratamento farmacológico , Humanos , Concentração Inibidora 50 , Plasma/metabolismo , Ratos , Especificidade por SubstratoRESUMO
The ionotropic glutamate receptor NMDA is allosterically modulated by glycine, a coagonist, its presence is an absolute requirement for receptor activation. The transport of glycine in glutamatergic synapse is carried out by glycine transporter-1 (GlyT1), a Na+/Cl(-)-dependent carrier molecule. The primary role of GlyT1 is to maintain glycine concentrations below saturation level at postsynaptic NMDA receptors. Several isoforms of GlyT1 (a-e) have been identified, which are expressed both in glial and neuronal cell membranes. GlyT1 operates bidirectionally: it decreases synaptic glycine concentration when operates in normal mode and releases glycine from glial cells as operates in a reverse mode. It is expected that non-transportable, non-competitive inhibitors of GlyT1 may have therapeutic value in CNS disorders characterized by hypofunctional NMDA receptor-mediated glutamatergic neurotransmission. Accordingly, GlyT1 inhibitors exhibited antipsychotic profile in a number of animal tests. The first promising in vitro and in vivo experiments with glycine itself, and its N-methyl analogue, sarcosine, had initiated the syntheses of potential GlyT1 inhibitors with more complex structures, in which, however, the glycine or sarcosine moiety had always been incorporated. Those attempts led to the development of two compounds, ALX-5407 and Org-24461 with high inhibitory potency; however, none of which is now considered as a drug candidate due, most probably, to safety and/or pharmacokinetic issues. More recently, several structurally new series of highly potent inhibitors with no aminomethylcarboxy group have also been discovered. Some of them might be expected to fulfill all requirements for clinical development. The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions.
Assuntos
Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Proteínas da Membrana Plasmática de Transporte de Glicina/fisiologia , Animais , Antipsicóticos/uso terapêutico , Transtornos de Ansiedade/genética , Glicina/metabolismo , Humanos , Receptores de N-Metil-D-Aspartato/metabolismo , Esquizofrenia/genética , Esquizofrenia/metabolismo , Esquizofrenia/prevenção & controleRESUMO
Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1, TRPV1) ion channels expressed on nociceptive primary sensory neurons are important regulators of pain and inflammation. TRPA1 is activated by several inflammatory mediators including formaldehyde and methylglyoxal that are products of the semicarbazide-sensitive amine-oxidase enzyme (SSAO). SZV-1287 is a new 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime SSAO inhibitor, its chemical structure is similar to other oxime derivatives described as TRPA1 antagonists. Therefore, we investigated its effects on TRPA1 and TRPV1 receptor activation on the cell bodies and peripheral terminals of primary sensory neurons and TRPA1 or TRPV1 receptor-expressing cell lines. Calcium influx in response to the TRPA1 agonist allyl-isothiocyanate (AITC) (200 µM) and the TRPV1 stimulator capsaicin (330 nM) in rat trigeminal neurons or TRPA1 and TRPV1 receptor-expressing cell lines was measured by microfluorimetry or radioactive (45)Ca(2+) uptake experiments. Calcitonin gene-related peptide (CGRP) release as the indicator of 100 µM AITC - or 100 nM capsaicin-induced peripheral sensory nerve terminal activation was measured by radioimmunoassay. SZV-1287 (100, 500 and 1000 nM) exerted a concentration-dependent significant inhibition on both AITC- and capsaicin-evoked calcium influx in trigeminal neurons and TRPA1 or TRPV1 receptor-expressing cell lines. It also significantly inhibited the TRPA1, but not the TRPV1 activation-induced CGRP release from the peripheral sensory nerve endings in a concentration-dependent manner. In contrast, the reference SSAO inhibitor LJP 1207 with a different structure had no effect on TRPA1 or TRPV1 activation in either model system. This is the first evidence that our novel oxime compound SZV-1287 originally developed as a SSAO inhibitor has a potent dual antagonistic action on TRPA1 and TRPV1 ion channels on primary sensory neurons.
Assuntos
Neurotransmissores/farmacologia , Oxazóis/farmacologia , Oximas/farmacologia , Fármacos do Sistema Sensorial/farmacologia , Canais de Potencial de Receptor Transitório/antagonistas & inibidores , Animais , Células CHO , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Cálcio/metabolismo , Capsaicina/farmacologia , Cátions Bivalentes/metabolismo , Linhagem Celular , Cricetulus , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Isotiocianatos/farmacologia , Estrutura Molecular , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Oxazóis/síntese química , Oxazóis/química , Oximas/síntese química , Oximas/química , Ratos Wistar , Fármacos do Sistema Sensorial/síntese química , Fármacos do Sistema Sensorial/química , Traqueia/inervação , Canais de Potencial de Receptor Transitório/agonistas , Canais de Potencial de Receptor Transitório/metabolismo , Gânglio Trigeminal/efeitos dos fármacos , Gânglio Trigeminal/fisiologiaRESUMO
Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.
Assuntos
Amina Oxidase (contendo Cobre) , Amina Oxidase (contendo Cobre)/antagonistas & inibidores , Amina Oxidase (contendo Cobre)/sangue , Amina Oxidase (contendo Cobre)/fisiologia , Arteriosclerose/tratamento farmacológico , Arteriosclerose/prevenção & controle , Vasos Sanguíneos/efeitos dos fármacos , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/enzimologia , Diabetes Mellitus/prevenção & controle , Inibidores Enzimáticos/uso terapêutico , Humanos , Estrutura MolecularRESUMO
The oxime formation reaction of therapeutical progestogen (levonorgestrel, levonorgestrel acetate, norethisterone), androgen (methyltestosterone, testosterone phenylpropionate) and anabolic (nortestosterone phenylpropionate) Delta(4)-3-ketosteroids has been investigated. The ketosteroid-hydroxylamine reaction was monitored by reversed phase HPLC system. It was established, that under the experimental conditions applied the oxime formation was complete within 2 h. The reaction leads to the formation of Z and E oxime isomers. The isomers of norgestimate (levonorgestrel 17-acetate oxime) and other Delta(4)-3-ketosteroid oximes have been separated by a new normal phase HPLC method. The identification (elution order assignation) and determination of the formation ratio of the isomers have been performed by 1H NMR spectroscopy on the basis of the chemical shift differences of 4-H signals. The on-line CD and UV spectra of the pure oxime isomers were recorded and then molar ellipticities and absorbances of the isomers were calculated in the wavelength range of 200-300 nm via parameter estimation method.
Assuntos
Cetosteroides/química , Norgestrel/análogos & derivados , Norgestrel/química , Oximas/química , Cromatografia Líquida de Alta Pressão , Dicroísmo Circular , Isomerismo , Espectroscopia de Ressonância Magnética , Oximas/síntese química , Espectrofotometria Ultravioleta , EstereoisomerismoRESUMO
The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 microM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD(90)) from 338.9 +/- 28.6 ms to 385.4 +/- 24 ms (n = 9, p > 0.05). This APD lengthening effect, unlike that of sotalol (30 microM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 microM), exerted a use-dependent depression of the maximal rate of depolarization (V(max)) which amounted to 36.4 +/- 11.7% at cycle length of 400 ms (n = 5, p < 0.05) and was characterised with an offset kinetical time constant of 298.6 +/- 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Assuntos
Amiodarona/farmacologia , Antiarrítmicos/farmacologia , Coração/efeitos dos fármacos , Mexiletina/farmacologia , Fenetilaminas/farmacologia , Sotalol/farmacologia , Sulfonamidas/farmacologia , Potenciais de Ação/efeitos dos fármacos , Adulto , Estimulação Elétrica , Eletrofisiologia , Feminino , Coração/fisiologia , Humanos , Técnicas In Vitro , Cinética , Masculino , Músculos Papilares/efeitos dos fármacos , Função Ventricular Direita/efeitos dos fármacosRESUMO
The effect of N-[4-[2-N-methyl-N-[1-methyl-2-(2, 6-dimethylphenoxy)ethylamino]-ethyl]-phenyl]-methanesulfonamide. hydrochloride (GYKI-16638; 0.03 and 0.1 mg/kg, i.v.), a novel antiarrhythmic compound, was assessed and compared to that of D-sotalol (1 and 3 mg/kg, i.v.) on arrhythmias induced by 10 min of coronary artery occlusion and 10 min of reperfusion in anaesthetized rabbits. Also, its cellular electrophysiological effects were studied in rabbit right ventricular papillary muscle preparations and in rabbit single isolated ventricular myocytes. In anaesthetized rabbits, intravenous administration of 0.03 and 0.1 mg/kg GYKI-16638 and 1 and 3 mg/kg D-sotalol significantly increased survival during reperfusion (GYKI-16638: 82% and 77%, D-sotalol: 75% and 83% vs. 18% in controls, P<0.05, respectively). GYKI-16638 (0.1 mg/kg) significantly increased the number of animals that did not develop arrhythmias during reperfusion (46% vs. 0% in controls, P<0.05). In isolated rabbit right ventricular papillary muscle, 2 microM GYKI-16638, at 1 Hz stimulation frequency, lengthened the action potential duration at 50% and 90% repolarization (APD(50-90)) without influencing the resting membrane potential and action potential amplitude (APA). It decreased the maximal rate of depolarization (V(max)) in a use-dependent manner. This effect was statistically significant only at stimulation cycle lengths shorter than 700 ms. The offset kinetics of this V(max) block were relatively rapid, the corresponding time constant for recovery of V(max) was 328.2+/-65.0 ms. In patch-clamp experiments, performed in rabbit ventricular myocytes, 2 microM GYKI-16638 markedly depressed the rapid component of the delayed rectifier outward and moderately decreased the inward rectifier K(+) current without significantly altering the slow component of the delayed rectifier and transient outward K(+) currents. These results suggest that in rabbits, GYKI-16638 has an in vivo antiarrhythmic effect, comparable to that of D-sotalol, which can be best explained by its combined Class I/B and Class III actions.
Assuntos
Arritmias Cardíacas/tratamento farmacológico , Coração/efeitos dos fármacos , Fenetilaminas/uso terapêutico , Sulfonamidas/uso terapêutico , Potenciais de Ação/efeitos dos fármacos , Anestesia , Animais , Antiarrítmicos/farmacologia , Arritmias Cardíacas/etiologia , Modelos Animais de Doenças , Eletrofisiologia , Coração/fisiologia , Ventrículos do Coração/citologia , Ventrículos do Coração/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Masculino , Isquemia Miocárdica/fisiopatologia , Miocárdio , Músculos Papilares/efeitos dos fármacos , Músculos Papilares/fisiologia , Fenetilaminas/farmacologia , Canais de Potássio/efeitos dos fármacos , Canais de Potássio/fisiologia , Coelhos , Reperfusão/efeitos adversos , Sotalol/farmacologia , Sotalol/uso terapêutico , Sulfonamidas/farmacologia , Fatores de Tempo , Função VentricularRESUMO
Ambasilide, a representative of Class III antiarrhythmics, was reported to prolong the cardiac action potential duration in the dog, with little or no effect on Ca and Na currents. We synthesised a series of ambasilide analogues, having the 3,8-diazabicyclo-[3.2.1]-octane moiety instead of the 3,7-diazabicyclo-[3.3.1]-nonane present in ambasilide. The compounds were tested both in vitro extracellular electrophysiological assays and by the conventional microelectrode technique. Most of them lengthened the effective refractory period (ERP) with no change or slight increase on the impulse conduction time (ICT). Similarly some of the tested compounds lengthened the action potential duration (APD), a typical Class III feature, without exerting any significant effect on the maximal rate of depolarization, therefore apparently lacking Class I antiarrhythmic activity.
Assuntos
Aminobenzoatos/química , Aminobenzoatos/farmacologia , Antiarrítmicos/química , Antiarrítmicos/síntese química , Antiarrítmicos/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/química , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Ventrículos do Coração/efeitos dos fármacos , Aminobenzoatos/síntese química , Animais , Compostos Bicíclicos Heterocíclicos com Pontes/síntese química , Cães , Desenho de Fármacos , Técnicas Eletrofisiológicas Cardíacas , Feminino , Técnicas In Vitro , Masculino , Microeletrodos , Modelos Moleculares , Conformação Molecular , Relação Estrutura-AtividadeRESUMO
In spite of the accelerated evolution in antiarrhythmic drug research and design, the ideal antiarrhythmic compound has not yet emerged. Pure class III agents have not been clinically successful, mainly due to their torsadogenic side-effects. Combination of class III effect with class I, II or IV effects has given better therapeutic results, whilst combination of the various antiarrhythmic mechanisms within one molecule, rather than combination of drugs, seems to be an even more promising strategy. In this study, we briefly review the most frequently applied antiarrhythmic combinations, focusing primarily to those novel antiarrhythmics where class III effects are combined with class IV or class I actions within the same single molecule.
RESUMO
Several 4,5-disubstituted 3(2H)-pyridazinone derivatives containing 2-hydroxymethylpyrrolidino moiety as a chiral building block were synthetized. Separation of enantiomers was carried out by chiral HPLC on Chiralcel OJ and OF columns. Mobile phases consisted of hexane, ethanol and 2-propanol. Chiralcel OJ column was capable of separating most of the enantiomeric pairs. For one type of compound. Chiralcel OF column was used for separation.
Assuntos
Piridazinas/isolamento & purificação , 2-Propanol/química , Benzoatos , Celulose/análogos & derivados , Cromatografia Líquida de Alta Pressão/métodos , Etanol/química , Hexanos/química , Rotação Ocular , Piridazinas/análise , Reprodutibilidade dos Testes , Estereoisomerismo , TemperaturaRESUMO
Research activities of the Hungarian Institute of Drug Research in the field of cardiovascular agents are reviewed. Many promising drug candidates were found including a compound already marketed. Novel concepts for drug research were developed as well.
Assuntos
Fármacos Cardiovasculares/farmacologia , Animais , Fármacos Cardiovasculares/síntese química , Indústria Farmacêutica , Humanos , Hungria , PesquisaRESUMO
The most significant achievements in the cardiovascular research areas have been reviewed. Among the beta-adrenoceptor blockers, antihypertensive, positive inotropic, and antiarrhythmic compounds synthesized and investigated at the IDR, a number of new drug candidates have been found and studied in clinical phases. One compound has been marketed (Tobanum, beta-adrenoceptor blocker).
Assuntos
Fármacos Cardiovasculares/síntese química , Academias e Institutos , Antagonistas Adrenérgicos beta/síntese química , Antiarrítmicos/síntese química , Anti-Hipertensivos/síntese química , Cardiotônicos/síntese química , Fármacos Cardiovasculares/química , Indústria Farmacêutica/tendências , Hungria , Estrutura Molecular , Pesquisa/tendênciasRESUMO
As an analogue of pyridazino-fused ring systems with pharmacological activities, the novel pyridazinol[3,4-b][1,5]diazepine ring system was prepared. The synthetic pathway includes three steps from 4 5-(N-benzyl-N-3-hydroxypropyl)amino derivative which is easily available through nucleophilic substitution reaction of the known 4,5-dichloro-2-methyl-6-nitro-3(2H)-pyridazinone (2) with N-benzyl-N-(3-hydroxypropyl)amine. In the first step, compound 4 was treated with thionyl chloride to give the chloropropyl derivative 5. In the second step, a Bechamp reduction was carried out with Fe in acetic acid to obtain the amino compound 6, and finally the ring closure reaction of 6 was performed in N,N-dimethylformamide in the presence of potassium carbonate at 110 degrees C for 40 hours. In this way the bicyclic compound 7 could be isolated in 48% yield.
Assuntos
Diazepam/análogos & derivados , Diazepam/síntese química , Piridazinas/química , Indicadores e Reagentes , Estrutura MolecularRESUMO
Among the indirect drug design approaches, the 3D QSAR methods have been of great importance. They now belong to the most attractive and effective modelling tools of modern drug research. In this review, three major topics will be covered. The first focuses on the conformational analysis, in the second part the DIstance COmparison (DISCO) strategy will be discussed, and in the last part the philosophy of the Comparative Molecular Field Analysis (CoMFA) will be briefly described and illustrated.
Assuntos
Desenho de Fármacos , Modelos Moleculares , Conformação Molecular , Relação Estrutura-Atividade , Simulação por Computador , Conformação Proteica , Proteínas/químicaRESUMO
Drug repositioning, an innovative therapeutic application of an old drug, has received much attention as a particularly costeffective strategy in drug R&D Recent work has indicated that repositioning can be promoted by utilizing a wide range of information sources, including medicinal chemical, target, mechanism, main and side-effect-related information, and also bibliometric and taxonomical fingerprints, signatures and knowledge bases. This article describes the adaptation of a conceptually novel, more efficient approach for the identification of new possible therapeutic applications of approved drugs and drug candidates, based on a kernel-based data fusion method. This strategy includes (1) the potentially multiple representation of information sources, (2) the automated weighting and statistically optimal combination of information sources, and (3) the automated weighting of parts of the query compounds. The performance was systematically evaluated by using Anatomical Therapeutic Chemical Classification System classes in a cross-validation framework. The results confirmed that kernel-based data fusion can integrate heterogeneous information sources significantly better than standard rank-based fusion can, and this method provides a unique solution for repositioning; it can also be utilized for de novo drug discovery. The advantages of kernel-based data fusion are illustrated with examples and open problems that are particularly relevant for pharmaceutical applications.
Assuntos
Descoberta de Drogas/métodos , Reposicionamento de Medicamentos , Armazenamento e Recuperação da Informação/métodos , Humanos , Máquina de Vetores de SuporteRESUMO
Glycine is a mandatory positive allosteric modulator of N-methyl-D-aspartate (NMDA)-type ionotropic glutamate receptors in the central nervous system. Elevation of glycine concentrations by inhibition of its reuptake in the vicinity of NMDA receptors may positively influence receptor functions as glycine B binding site on NR1 receptor subunit is not saturated in physiological conditions. Synaptic and extrasynaptic concentrations of glycine are regulated by its type-1 glycine transporter, which is primarily expressed in astroglial and glutamatergic cell membranes. Alteration of synaptic glycine levels may have importance in the treatment of various forms of endogenous psychosis characterized by hypofunctional NMDA receptors. Several lines of evidence indicate that impaired NMDA receptor-mediated glutamatergic neurotransmission is involved in development of the negative (and partly the positive) symptoms and the cognitive deficit in schizophrenia. Inhibitors of glycine transporter type-1 may represent a newly developed therapeutic intervention in treatment of this mental illness. We have synthesized a novel series of N-substituted sarcosines, analogues of the glycine transporter-1 inhibitor NFPS (N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine). Of the pyridazinone-containing compounds, SzV-1997 was found to be a potent glycine transporter-1 inhibitor in rat brain synaptosomes and it markedly increased extracellular glycine concentrations in conscious rat striatum. SzV-1997 did not exhibit toxic symptoms such as hyperlocomotion, restless movements, respiratory depression, and lethality, characteristic for NFPS. Besides pyridazinone-based, sarcosine-containing glycine transporter-1 inhibitors, a series of substrate-type amino acid inhibitors was investigated in order to obtain better insight into the ligand-binding characteristics of the substrate binding cavity of the transporter.
Assuntos
Química Encefálica/fisiologia , Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Proteínas da Membrana Plasmática de Transporte de Glicina/fisiologia , Glicina/fisiologia , Receptores de N-Metil-D-Aspartato/fisiologia , Animais , Proteínas da Membrana Plasmática de Transporte de Glicina/química , Humanos , Sarcosina/farmacologiaRESUMO
The role of α(2)-adrenoceptors in regulation of gastric motility has been well documented. However, only few data are available on the adrenoceptor subtype that mediates this effect. The purpose of the present work was to identify the α(2)-adrenoceptor subtype(s) responsible for the inhibition of gastric motor activity in isolated fundus strip of the mouse. It was shown that (i) the electrically evoked contraction of the gastric fundus strip of the mouse was inhibited by the non-selective α(2)-adrenoceptor stimulant clonidine (EC(50): 0.019±0.001µM), the α(2A)-adrenoceptor subtype selective agonist oxymetazoline (EC(50): 0.004±0.001µM) and the α(2B)-adrenoceptor subtype preferring ST-91 (EC(50): 0.029±0.004µM), (ii) the inhibitory effect of clonidine (1µM), oxymetazoline (0.1µM) and ST-91 (1µM) on the contractions of gastric fundus strip was reversed by the non-selective α(2)-adrenoceptor antagonist idazoxan and α(2A)-adrenoceptor antagonist BRL 44408, but not by the α(2B/2C)-adrenoceptor antagonist ARC-239. (iii) Clonidine and ST-91 inhibited the electrically induced gastric contractions in C57BL/6 wild type mice as well as in α(2B)- and α(2C)-adrenoceptor deficient mice in a concentration-dependent manner; however, neither of them was effective in α(2A)-deficient mice. As a conclusion, it was first demonstrated that the inhibitory effect of α(2)-adrenoceptor agonists on the gastric motor activity of isolated stomach strip of the mouse is mediated purely by α(2A)-adrenoceptors.